PH24873A - Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent - Google Patents

Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent

Info

Publication number
PH24873A
PH24873A PH37884A PH37884A PH24873A PH 24873 A PH24873 A PH 24873A PH 37884 A PH37884 A PH 37884A PH 37884 A PH37884 A PH 37884A PH 24873 A PH24873 A PH 24873A
Authority
PH
Philippines
Prior art keywords
dione
thiazolidine
benzopyran
dihydro
benzyl
Prior art date
Application number
PH37884A
Other languages
English (en)
Inventor
Michael Norman Krupp
Archie Calhoun Swindell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PH24873A publication Critical patent/PH24873A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PH37884A 1987-12-02 1988-12-02 Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent PH24873A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/127,858 US4798835A (en) 1987-12-02 1987-12-02 dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent

Publications (1)

Publication Number Publication Date
PH24873A true PH24873A (en) 1990-12-26

Family

ID=22432331

Family Applications (1)

Application Number Title Priority Date Filing Date
PH37884A PH24873A (en) 1987-12-02 1988-12-02 Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent

Country Status (16)

Country Link
US (1) US4798835A (ko)
EP (1) EP0319288B1 (ko)
JP (1) JPH01186883A (ko)
KR (1) KR900006993B1 (ko)
AT (1) ATE81456T1 (ko)
AU (1) AU604176B2 (ko)
CA (1) CA1313139C (ko)
DE (1) DE3875324T2 (ko)
DK (1) DK670988A (ko)
HU (1) HU204433B (ko)
IE (1) IE883600L (ko)
IL (1) IL88513A (ko)
MY (1) MY103498A (ko)
PH (1) PH24873A (ko)
PT (1) PT89123B (ko)
ZA (1) ZA888968B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
EP0715853A1 (en) * 1991-01-10 1996-06-12 Transcend Therapeutics, Inc. Use of glutathione esters for the treatment of pulmonary diseases
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
US5866595A (en) * 1991-09-26 1999-02-02 The Regents Of The University Of California Calcium antagonists for treatment of vascular restenosis
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (ja) * 1982-01-07 1983-07-14 Takeda Chem Ind Ltd チアゾリジン誘導体
US4617312A (en) * 1983-01-17 1986-10-14 Pfizer Inc. Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物

Also Published As

Publication number Publication date
DE3875324T2 (de) 1993-02-25
PT89123B (pt) 1993-09-30
DE3875324D1 (de) 1992-11-19
EP0319288A3 (en) 1990-12-27
DK670988D0 (da) 1988-12-01
ATE81456T1 (de) 1992-10-15
AU604176B2 (en) 1990-12-06
KR890009922A (ko) 1989-08-04
HU204433B (en) 1992-01-28
KR900006993B1 (ko) 1990-09-25
AU2647188A (en) 1989-06-08
CA1313139C (en) 1993-01-26
PT89123A (pt) 1989-12-29
JPH0460582B2 (ko) 1992-09-28
IE883600L (en) 1989-06-02
ZA888968B (en) 1990-07-25
HUT54045A (en) 1991-01-28
EP0319288A2 (en) 1989-06-07
IL88513A0 (en) 1989-06-30
IL88513A (en) 1994-04-12
DK670988A (da) 1989-07-24
US4798835A (en) 1989-01-17
EP0319288B1 (en) 1992-10-14
MY103498A (en) 1993-06-30
JPH01186883A (ja) 1989-07-26

Similar Documents

Publication Publication Date Title
DE3668892D1 (en) Hypoglycemische thiazolidinedione.
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
DZ2653A1 (fr) Procédé de préparation de dérivés de la classe destaxoïdes.
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
IE802661L (en) Isoquinoline acetic acids
PH24873A (en) Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
PT87197A (pt) Processo para preparacao de agentes terapeuticos eritropoietina
AU1083488A (en) Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus
DZ2430A1 (fr) Procédé pour la préparation de dérivés de thiazolidinedione substitués.
KR900009647A (ko) 아데노신 유도체, 그들의 제법 및 사용방법
NO905364L (no) Fremgangsmaate ved fremstilling av alkansyrederivater.
AU7935887A (en) Therapeutic agent for the treatment of peptic ulcer disease
EP0292352A3 (fr) Nouveaux dérivés macrolides, leur procédé de préparation et les compositions pharmaceutiques les contenant
EP0378146A3 (en) Polyamine derivatives as antineoplastic agents
FR2696745B1 (fr) Procédé de préparation de dérivés de phényltétrazole.
WO1999021538A3 (de) Verwendung von glykosaminoglykanen zur herstellung von pharmazeutischen zubereitungen zur behandlung von mit diabetes assoziierten augenkrankheiten
GB2197199B (en) Medicament for treatment of pregnancy-induced hypertension.
NO166789C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv kalsium-10-propyl-2,8-bis(1h-tetrazol-5-yl)-4h, 6h-benzo(1,2-b;5,4-b')di-pyran-4,6-dion.
GB2201343B (en) Ponalrestat as a hypouricaemic agent
NO891996L (no) Forbedret fremgangsmaate for fremstilling av 3-((4-brom-2-fluorfenyl)-methyl)-3, 4-dihydro-4-oxo-l-fthalazin-eddiksyre.